PROTEIOS TECHNOLOGY, INC.

Issaquah, WA · Biotech · Private

Tag-free, antibody-free cell separation platform using proprietary protein technology and nucleic acid aptamers for isolating cell subpopulations in research and manufacturing

Claim this profile

Follows are private to you and power your alerts

Updated · proteios.com

Sector
Biotech
Headquarters
Issaquah, WA
Total capital
$6.2M
Federal grants
$3.7M
6 awards · 2018–2023
Rank in peer group#20 of 36
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$2.5M
2 awards · Health and Human S
Rank in Biotech#125 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $6.2M$279K$750K$455K$1.6M$779K$2M
201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $6.2M$750K$1.6M$779K$2M

Latest events

  • Federal contractHealth and Human S · SBIR Phase II, Topic 429: A New Paradigm For Autologous And Allogeneic Cell Therapy Manufacturing$2M
  • Federal grantHealth and Human S · Phase II · Simple and Effective Method for Cell Separation During Preclinical Research and Cell Therapy Manufacturing$779K
  • Federal grantHealth and Human S · Phase II · Simple and Effective Method for Cell Separation During Preclinical Research and Cell Therapy Manufacturing$1.6M
  • Federal contractHealth and Human S · Topic 429 A New Paradigm For Autologous And Allogeneic Cell Therapy Manufacturing Period Of Performance September 13, 2021-JUNE 12, 2022 FY21 Phase I SBIR$455K
  • Federal grantNSF · Phase II · SBIR Phase II: Removing the Purification Bottleneck in Biopharmaceutical Production$750K
  • Federal grantHealth and Human S · Phase I · Simple and Effective Method for Cell Enrichment and Cell Depletion During Cell Therapy$55K
  • Federal grantHealth and Human S · Phase I · Simple and Effective Method for Cell Enrichment and Cell Depletion During Cell Therapy$279K
Show 1 earlier federal award
  • Federal grantNSF · Phase I · SBIR Phase I: Removing the Purification Bottleneck in Biopharmaceutical Production$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 36 peers

Line = median

Biotech · Platform

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .